US drugmaker Bristol Myers Squibb (NYSE: BMY) has sought to portray a Phase II failure for deucravacitinib as a rare setback for its selective tyrosine kinase 2 (TYK2) inhibitor.
Compared to placebo, deucravacitinib did not meet the primary efficacy endpoint of clinical remission at week 12, nor secondary efficacy endpoints, in the LATTICE-UC trial in ulcerative colitis (UC).
BMS is continuing with another trial of the drug in ulcerative colitis, including with a higher dose, and the company is also investigating its use in multiple immune-mediated diseases, among them psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze